Polidocanol: A Review of Off-Label Dermatologic Uses.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Polidocanol is an FDA-approved treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, but numerous other off-label dermatological applications have been reported. To describe the various off-label dermatological clinical uses of polidocanol, as well as efficacy and adverse effects. The review of studies searchable on PubMed from 2004 to 2021 describing clinical uses of polidocanol to determine efficacy and adverse effects associated with various dermatologic applications. Polidocanol has shown efficacy in the treatment of mucocele of minor salivary gland, hemangioma, upper extremity veins, reticular veins of the chest, facial veins, pyogenic granuloma, lymphangioma circumscriptum, digital mucous cyst, mixed skin ulcers, cutaneous focal mucinosis, seromas, glomuvenous malformations, acne cysts, lymphocele, and dissecting cellulitis. Commonly reported side effects include pain, erythema, swelling, ecchymosis, and ulceration. Most sources were case reports and small prospective studies, as such the strength of data supporting many uses is limited by small sample sizes and lack of controls. Although polidocanol is currently only FDA approved for incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, the use of polidocanol has been selected for a variety of off-label clinical applications.
Sections du résumé
BACKGROUND
Polidocanol is an FDA-approved treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, but numerous other off-label dermatological applications have been reported.
OBJECTIVE
To describe the various off-label dermatological clinical uses of polidocanol, as well as efficacy and adverse effects.
METHODS
The review of studies searchable on PubMed from 2004 to 2021 describing clinical uses of polidocanol to determine efficacy and adverse effects associated with various dermatologic applications.
RESULTS
Polidocanol has shown efficacy in the treatment of mucocele of minor salivary gland, hemangioma, upper extremity veins, reticular veins of the chest, facial veins, pyogenic granuloma, lymphangioma circumscriptum, digital mucous cyst, mixed skin ulcers, cutaneous focal mucinosis, seromas, glomuvenous malformations, acne cysts, lymphocele, and dissecting cellulitis. Commonly reported side effects include pain, erythema, swelling, ecchymosis, and ulceration. Most sources were case reports and small prospective studies, as such the strength of data supporting many uses is limited by small sample sizes and lack of controls.
CONCLUSION
Although polidocanol is currently only FDA approved for incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, the use of polidocanol has been selected for a variety of off-label clinical applications.
Identifiants
pubmed: 36054050
doi: 10.1097/DSS.0000000000003520
pii: 00042728-202209000-00012
doi:
Substances chimiques
Sclerosing Solutions
0
Polidocanol
0AWH8BFG9A
Types de publication
Journal Article
Review
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
961-966Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2022 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Parsi K. Interaction of detergent sclerosants with cell membranes. Phlebology 2015;30:306–15.
Sclerotherapy (6th ed). Available at: https://www.elsevier.com/books/sclerotherapy/goldman/978-0-323-37726-3 . Accessed December 26, 2021.
Parsi K, Exner T, Connor DE, Herbert A, et al. The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro. Eur J Vasc Endovasc Surg 2008;36:216–23.
Peterson JD, Goldman MP, Weiss RA, Duffy DM, et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg 2012;38:1322–30.
Eckmann DM. Polidocanol for endovenous microfoam sclerosant therapy. Expert Opin Investig Drugs 2009;18:1919–27.
Parsi K, Exner T, Low J, Fung Ma DD, et al. In vitro effects of detergent sclerosants on clot formation and fibrinolysis. Eur J Vasc Endovasc Surg 2011;41:267–77.
Miranda LA, do Carmo RC, Sathler-Melo CC, de Castro-Santos G. Bilateral foam polidocanol sclerotherapy of great saphenous veins and their tributaries in synchronous procedure. J Vasc Bras 2021;20:e20200178.
Hsu TS, Weiss RA. Foam sclerotherapy: a new era. Arch Dermatol 2003;139:1494–6.
Coleridge Smith P. Saphenous ablation: sclerosant or sclerofoam? Semin Vasc Surg 2005;18:19–24.
Whiteley MS, Patel SB. Modified Tessari Tourbillon technique for making foam sclerotherapy with silicone-free syringes. Phlebology 2015;30:614–7.
Rao J, Goldman MP. Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double-syringe system technique. Dermatol Surg 2005;31:19–22.
Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001;27:58–60.
021201lbl.pdf. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021201lbl.pdf . Accessed August 8, 2021.
Mann M, Munavalli GS, Amatangelo L, Morrison N. Improper potency and impurities in compounded polidocanol. J Drugs Dermatol 2019;18:1124–7.
Goldman MP. Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe? Dermatol Surg 2004;30:1454–6; discussion 1456.
Weiss RA, Voigts R, Howell DJ. Absence of concentration congruity in six compounded polidocanol samples obtained for leg sclerotherapy. Dermatol Surg 2011;37:812–5.
Almeida JI, Raines JK. FDA-approved sodium tetradecyl sulfate (STS) versus compounded STS for venous sclerotherapy. Dermatol Surg 2007;33:1037–44; discussion 1044.
Goldman MP, Kaplan RP, Oki LN, Cavender PA, et al. Sclerosing agents in the treatment of telangiectasia. Comparison of the clinical and histologic effects of intravascular polidocanol, sodium tetradecyl sulfate, and hypertonic saline in the dorsal rabbit ear vein model. Arch Dermatol 1987;123:1196–201.
Khunger N, Sacchidanand S. Standard guidelines for care: sclerotherapy in dermatology. Indian J Dermatol Venereol Leprol 2011;77:222–31.
Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg 2005;31:631–5.
Yiannakopoulou E. Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins. Pharmacology 2016;98:62–9.
Alòs J, Carreño P, López JA, Estadella B, et al. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg 2006;31:101–7.
Roselli A, Khouri C, Roustit M, Blaise S, et al. Safety profile of sclerosing agents: an analysis from the World Health Organization Pharmacovigilance Database VigiBase. Dermatol Surg 2019;45:1517–28.
Cavezzi A, Parsi K. Complications of foam sclerotherapy. Phlebology 2012;27(Suppl 1):46–51.
Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg 2002;28:52–5.
Liu JL, Zhang AQ, Jiang LC, Li KY, et al. The efficacy of polidocanol sclerotherapy in mucocele of the minor salivary gland. J Oral Pathol Med 2018;47:895–9.
Gao Z, Zhang Y, Li W, Shi C. Effectiveness and safety of polidocanol for the treatment of hemangiomas and vascular malformations: a meta-analysis. Dermatol Ther 2018;31:e12568.
Winter H, Dräger E, Sterry W. Sclerotherapy for treatment of hemangiomas. Dermatol Surg 2000;26:105–8.
Grover C, Arora P, Kedar A, Pal P, et al. Combination of oral corticosteroids and polidocanol sclerotherapy in the management of infantile hemangiomas. Dermatol Surg 2010;36:2030–6.
Grover C, Khurana A, Bhattacharya SN. Sclerotherapy for the treatment of infantile hemangiomas. J Cutan Aesthet Surg 2012;5:201–3.
Uslu M, Beşir H, Turan H, Bozkaya H, et al. Two different treatment options for intramuscular plantar hemangioma: surgery versus percutaneous sclerotherapy. J Foot Ankle Surg 2014;53:759–62.
Seale KS, Lange TA, Monson D, Hackbarth DA. Soft tissue tumors of the foot and ankle. Foot Ankle 1988;9:19–27.
Kirby EJ, Shereff MJ, Lewis MM. Soft-tissue tumors and tumor-like lesions of the foot. An analysis of eighty-three cases. J Bone Joint Surg Am 1989;71:621–6.
Matsuo T, Fujiwara H, Gobara H, Mimura H, et al. Central retinal and posterior ciliary artery occlusion after intralesional injection of sclerosant to glabellar subcutaneous hemangioma. Cardiovasc Intervent Radiol 2009;32:341–6.
Duffy DM, Garcia C, Clark RE, Angeles LC. The role of sclerotherapy in abnormal varicose hand veins. Plast Reconstr Surg 1999;104:1474–9.
Grieb D, Meila D, Greling B, Jacobs C, et al. Craniofacial venous malformations treated by percutaneous sclerotherapy using polidocanol: a single-center experience. Acta Radiol 2019;60:593–601.
Bowes LE, Goldman MP. Sclerotherapy of reticular and telangiectatic veins of the face, hands, and chest. Dermatol Surg 2002;28:46–51.
Green D. Removal of periocular veins by sclerotherapy. Ophthalmology 2001;108:442–8.
Goldman MP, Weiss RA, Brody HJ, Coleman WP, et al. Treatment of facial telangiectasia with sclerotherapy, laser surgery, and/or electrodesiccation: a review. J Dermatol Surg Oncol 1993;19:899–10. quiz 909-910.
Fante RG, Goldman MP. Removal of periocular veins by sclerotherapy: editorial. Ophthamology 2001;180:433–4.
Fante RG, Goldman MP. Removal of periocular veins by sclerotherapy. Ophthalmology 2001;108:433–4.
Kuo HW, Yang CH. Venous lake of the lip treated with a sclerosing agent: report of two cases. Dermatol Surg 2003;29:425–8.
Bowes LE, Goldman MP. Sclerotherapy of reticular and telangiectatic veins of the face, hands, and chest. Dermatol Surg 2002;28:46–51.
Peterson J, Goldman MP. Rejuvenation of the chest: a review. Dermatol Surg 2011;37:555–71.
Carvalho RA, Neto V. Letter: polidocanol sclerotherapy for the treatment of pyogenic granuloma. Dermatol Surg 2010;36(Suppl 2):1068–70.
Niti K, Manish P. Microcystic lymphatic malformation (lymphangioma circumscriptum) treated using a minimally invasive technique of radiofrequency ablation and sclerotherapy. Dermatol Surg 2010;36:1711–7.
Esson GA, Holme SA. Treatment of 63 subjects with digital mucous cysts with percutaneous sclerotherapy using polidocanol. Dermatol Surg 2016;42:59–62.
Córdoba S, Romero A, Hernández-Nuñez A, Borbujo JM. Treatment of digital mucous cysts with percutaneous sclerotherapy using polidocanol. Dermatol Surg 2008;34:1387–8.
Lloret P, Redondo P, Sierra A, Cabrera J. Mixed skin ulcers misdiagnosed as pyoderma gangrenosum and rheumatoid ulcer: successful treatment with ultrasound-guided injection of polidocanol microfoam. Dermatol Surg 2006;32:749–52.
Juhl ME, Sidiropoulos M, Antonijevic S, Lyon M, et al. Focal cutaneous mucinosis after knee replacement: a rare entity successfully treated with intralesional polidocanol. JAAD Case Rep 2017;3:16–8.
Moritz RK, Reich-Schupke S, Altmeyer P, Stücker M. Polidocanol foam sclerotherapy of persisting postoperative seromas after varicose vein surgery: a series of six cases. Phlebology 2013;28:341–6.
Jha A, Khunger N, Malarvizhi K, Ramesh V, et al. Familial disseminated cutaneous glomuvenous malformation: treatment with polidocanol sclerotherapy. J Cutan Aesthet Surg 2016;9:266–9.
Bhattacharjee R, Kumar S, Vinay K, Narang T, et al. Intralesional sclerotherapy for the treatment of acne cysts: a case series. Dermatol Ther 2020;33:e13505.
Klode J, Klötgen K, Körber A, Schadendorf D, et al. Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele. J Eur Acad Dermatol Venereol 2010;24:904–9.
Aboul-Fettouh N, Silapunt S, Mays S, Nguyen T. Intracavitary foam sclerotherapy in dissecting cellulitis of the scalp. Dermatol Surg 2021;47:1317–9.